The effect of postoperative gemcitabine on overall survival in patients with resected pancreatic cancer: A nationwide population-based Danish register study

References

• Malvezzi M, Carioli G, Bertuccio P, et al. European cancer mortality predictions for the year 2016 with focus on leukaemias. Ann Oncol. 2016;27:725–731.
   PubMed Web of Science ®Google Scholar
• Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391:1023–1075.
   PubMed Web of Science ®Google Scholar
• Storm HH, Gislum M, Engholm G. Kræftoverlevelse før og efter den danske kræftplan [Cancer survival before and after initiating the Danish Cancer Control plan]. Ugeskr Laeger. 2008;170:3065–3069.
   PubMedGoogle Scholar
• Kleeff J, Korc M, Apte M, et al. Pancreatic cancer. Nat Rev Dis Prim. 2016;2:1–23.
   Web of Science ®Google Scholar
• Engholm G, Ferlay J, Christensen N, et al. NORDCAN – a Nordic tool for cancer information, planning, quality control and research. Acta Oncol. 2010;49:725–736.
   PubMed Web of Science ®Google Scholar
• Dansk Pancreas Cancer Database, Årssrapport 2015/2016 [Internet] [Danish Pancreatic Cancer Database Annual Report 2015/2016]. Available from: http://dpcg.gicancer.dk/Content/Files/Dokumenter/Databaserapporter/dpcd_aarsrapport_2015_2016_officiel_version_f.pdf. Danish.
   Google Scholar
• Schmidt M, Pedersen L, Sørensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol. 2014;29:541–549.
   PubMed Web of Science ®Google Scholar
• Schmidt M, Schmidt SAJ, Sandegaard JL, et al. The Danish National Patient Registry: a review of content. Data Qual Res Potential Clin Epidemiol. 2015;7:449–490.
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: A randomised controlled trial. Lancet. 2001;358:1576–1585.
   PubMed Web of Science ®Google Scholar
• Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267–277.
   PubMed Web of Science ®Google Scholar
• Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310:1473–1481.
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer resection: a randomized controlled trial. JAMA. 2010;304:1073–1081.
   PubMed Web of Science ®Google Scholar
• Dansk Pancreas Cancer Gruppe, Nationale Kliniske Retningslinier 2015 [Internet] [Danish Pancreatic Cancer Group National Clinical Guidelines 2015]. Danish. Available from: http://dpcg.gicancer.dk/Default.aspx?pID=22
   Google Scholar
• Sorbye H, Pfeiffer P, Cavalli-Björkman N, et al. Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients. Cancer. 2009;115:4679–4687.
   PubMed Web of Science ®Google Scholar
• Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med. 2018;379:2395–2406.
   PubMed Web of Science ®Google Scholar
• Fristrup C, Detlefsen S, Hansen CP, et al. Danish Pancreatic Cancer Database. Clin Epidemiol. 2016;8:645–648.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383.
   PubMedGoogle Scholar
• Bosman FT, Carneiro F, Hruban RH, et al. WHO Classification of Tumours of the Digestive System. 4th ed. Lyon (France): International Agency for Research on Cancer; 2010.
   Google Scholar
• Sobin LH, Gospodarowicz M, Wittekind C. TNM Classification of Malignant Tumours. 7th edition. New York: International Union Against Cancer (UICC); 2009.
   Google Scholar
• Verbeke CS. Resection Margins in Pancreatic Cancer. Surg Clin North Am. 2013;93:647–662.
   PubMed Web of Science ®Google Scholar
• Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol. 1983;1:710–719.
   PubMed Web of Science ®Google Scholar
• Mi X, Hammill BG, Curtis LH, et al. Use of the landmark method to address immortal person-time bias in comparative effectiveness research: a simulation study. Stat Med. 2016;35:4824–4836.
   PubMed Web of Science ®Google Scholar
• Huang L, Jansen L, Balavarca Y, et al. Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations. Gut. 2019;68:130–139.
   PubMed Web of Science ®Google Scholar
• Tjarda Van Heek N, Kuhlmann KFD, Scholten RJ, et al. Hospital volume and mortality after pancreatic resection: A systematic review and an evaluation of intervention in the Netherlands. Ann Surg. 2005;242:781–790.
   PubMed Web of Science ®Google Scholar
• Xu J-B, Jiang B, Chen Y, et al. Optimal adjuvant chemotherapy for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis. Oncotarget. 2017;8:81419–81429.
   PubMedGoogle Scholar
• Bakens MJ, van der Geest LG, van Putten M, et al. The use of adjuvant chemotherapy for pancreatic cancer varies widely between hospitals: a nationwide population-based analysis. Cancer Med. 2016;5:2825–2831.
   PubMed Web of Science ®Google Scholar
• Labori KJ, Katz MH, Tzeng CW, et al. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma – A population-based cohort study. Acta Oncol. 2016;55:265–277.
   PubMed Web of Science ®Google Scholar
• Wu W, He J, Cameron JL, et al. The impact of postoperative complications on the administration of adjuvant therapy following pancreaticoduodenectomy for adenocarcinoma. Ann Surg Oncol. 2014;21:2873–2881.
   PubMed Web of Science ®Google Scholar
• Ueno H, Kosuge T, Matsuyama Y, et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer. 2009;101:908–915.
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;6736:1–14.
   Google Scholar
• Åkerberg D, Björnsson B, Ansari D. Factors influencing receipt of adjuvant chemotherapy after surgery for pancreatic cancer: a two-center retrospective cohort study. Scand J Gastroenterol. 2017;52:56–60.
   PubMed Web of Science ®Google Scholar
• Kagedan DJ, Raju RS, Dixon ME, et al. The association of adjuvant therapy with survival at the population level following pancreatic adenocarcinoma resection. HPB. 2016;18:339–347.
   PubMed Web of Science ®Google Scholar
• Parikh AA, Maiga A, Bentrem D, et al. Adjuvant therapy in pancreas cancer: does it influence patterns of recurrence? J Am Coll Surg. 2016;222:448–456.
   PubMed Web of Science ®Google Scholar
• Valle JW, Palmer D, Jackson R, et al. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: Ongoing lessons from the ESPAC-3 study. J Clin Oncol. 2014;32:504–512.
   PubMed Web of Science ®Google Scholar
• Murakami Y, Uemura K, Sudo T, et al. Early initiation of adjuvant chemotherapy improves survival of patients with pancreatic carcinoma after surgical resection. Cancer Chemother Pharmacol. 2013;71:419–429.
   PubMed Web of Science ®Google Scholar
• Riediger H, Keck T, Wellner U, et al. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J Gastrointest Surg. 2009;13:1337–1344.
   PubMed Web of Science ®Google Scholar
• Vanderveen KA, Chen SL, Yin D, et al. Benefit of postoperative adjuvant therapy for pancreatic cancer: A population-based analysis. Cancer. 2009;115:2420–2429.
   PubMed Web of Science ®Google Scholar
• Haeno H, Gonen M, Davis MB, et al. Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell. 2012;148:362–375.
   PubMed Web of Science ®Google Scholar
• Uesaka K, Boku N, Fukutomi A, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388:248–257.
   PubMed Web of Science ®Google Scholar
• Clinicaltrails.gov. Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer (NEONAX) [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT02047513.
   Google Scholar
• Clinicaltrails.gov. Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX for Resectable Pancreas Carcinoma [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT02172976.
   Google Scholar
• Reni M, Balzano G, Zanon S, et al. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2–3 trial. Lancet Gastroenterol Hepatol. 2018;3:413–423.
   PubMed Web of Science ®Google Scholar
• Tas F, Sen F, Odabas H, et al. Performance status of patients is the major prognostic factor at all stages of pancreatic cancer. Int J Clin Oncol. 2013;18:839–846.
   PubMed Web of Science ®Google Scholar
• Delpero JR, Jeune F, Bachellier P, et al. Prognostic value of resection margin involvement after pancreaticoduodenectomy for ductal adenocarcinoma: updates from a French Prospective Multicenter Study. Ann Surg. 2017;266:787–796.
   PubMed Web of Science ®Google Scholar